Wire · opportunities
FDA Approves Camizestrant (Etcamah) for Advanced HR+/HER2
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA has granted accelerated approval to camizestrant (Etcamah), a selective estrogen receptor degrader (SERD), for use with CDK4/6 inhibitors to treat advanced hormone receptor-positive, HER2-negative breast cancer with ESR1 mutations after prior aromatase inhibitor and CDK4/6 inhibitor therapy. Approval is based on the SERENA-6 study showing improved progression-free survival compared to continuing prior therapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 4 Sep 2026 and 11 Sep 2026.
◆ ◆ The Wire takeaway
Cancer drug developers focusing on hormonal therapies must now factor in camizestrant's FDA approval when targeting ESR1-mutated breast cancers. You need to evaluate incorporating ESR1 mutation testing and consider camizestrant as a competitive baseline for any new endocrine treatments.
◆ Coverage
15 sources · first reported 4 Sep 2026 · latest 11 Sep 2026
◆ Topics